Rapamycin-Induced/JJ
Abundance/NN
Changes/NNS
in/IN
the/DT
Proteome/NN
of/IN
Budding/JJ
Yeast/NN
./.
====================
The/DT
target/NN
of/IN
rapamycin/NN
(/(
TOR/NN
)/)
signaling/NN
pathway/NN
conserved/VBN
from/IN
yeast/NN
to/TO
human/JJ
plays/VBZ
critical/JJ
roles/NNS
in/IN
regulation/NN
of/IN
eukaryotic/JJ
cell/NN
growth/NN
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
TOR/NN
pathway/NN
is/VBZ
involved/VBN
in/IN
several/JJ
cellular/JJ
processes/NNS
,/,
including/VBG
ribosome/NN
biogenesis/NN
,/,
nutrient/JJ
response/NN
,/,
autophagy/NN
and/CC
aging/NN
./.
====================
However/RB
,/,
due/JJ
to/TO
the/DT
functional/JJ
diversity/NN
of/IN
TOR/NN
pathway/NN
,/,
we/PRP
do/VBP
not/RB
know/VB
yet/RB
some/DT
key/JJ
effectors/NNS
of/IN
the/DT
pathway/NN
./.
====================
To/TO
find/VB
unknown/JJ
effectors/NNS
of/IN
TOR/NN
signaling/NN
pathway/NN
,/,
we/PRP
took/VBD
advantage/NN
of/IN
a/DT
green/JJ
fluorescent/JJ
protein/NN
(/(
GFP/NN
)/)
-tagged/JJ
collection/NN
of/IN
budding/VBG
yeast/NN
Saccharomyces/FW
cerevisiae/NN
./.
====================
We/PRP
analyzed/VBD
protein/NN
abundance/NN
changes/NNS
by/IN
measuring/VBG
the/DT
GFP/NN
fluorescence/NN
intensity/NN
of/IN
4156/CD
GFP-tagged/JJ
yeast/NN
strains/NNS
under/IN
inhibition/NN
of/IN
TOR/NN
pathway/NN
./.
====================
Our/PRP$
proteomic/JJ
analysis/NN
argues/VBZ
that/DT
83/CD
proteins/NNS
are/VBP
decreased/VBN
whereas/IN
32/CD
proteins/NNS
are/VBP
increased/VBN
by/IN
treatment/NN
of/IN
rapamycin/NN
,/,
a/DT
specific/JJ
inhibitor/NN
of/IN
TOR/NN
complex/NN
1/CD
(/(
TORC1/NN
)/)
./.
====================
We/PRP
found/VBD
that/IN
,/,
among/IN
the/DT
115/CD
proteins/NNS
that/WDT
show/VBP
significant/JJ
changes/NNS
in/IN
protein/NN
abundance/NN
under/IN
rapamycin/NN
treatment/NN
,/,
37/CD
proteins/NNS
also/RB
show/VBP
expression/NN
changes/NNS
in/IN
the/DT
mRNA/NN
levels/NNS
by/IN
more/RBR
than/IN
2-fold/JJ
under/IN
the/DT
same/JJ
condition/NN
./.
====================
We/PRP
suggest/VBP
that/IN
the/DT
115/CD
proteins/NNS
indentified/VBD
in/IN
this/DT
study/NN
may/MD
be/VB
directly/RB
or/CC
indirectly/RB
involved/VBN
in/IN
TOR/NN
signaling/NN
and/CC
can/MD
serve/VB
as/IN
candidates/NNS
for/IN
further/JJ
investigation/NN
of/IN
the/DT
effectors/NNS
of/IN
TOR/NN
pathway/NN
./.
====================
The/DT
target/NN
of/IN
rapamycin/NN
(/(
TOR/NN
)/)
kinase/NN
is/VBZ
highly/RB
conserved/VBN
from/IN
yeast/NN
to/TO
human/JJ
and/CC
specifically/RB
inhibited/VBD
by/IN
a/DT
macrolide/NN
antibiotic/JJ
,/,
rapamycin/NN
./.
====================
It/PRP
is/VBZ
known/VBN
that/IN
TOR/NN
kinase/NN
functions/NNS
as/IN
a/DT
key/JJ
regulator/NN
of/IN
eukaryotic/JJ
cell/NN
growth/NN
and/CC
development/NN
(/(
Wullschleger/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
TOR/NN
kinase/NN
exists/VBZ
in/IN
two/CD
functionally/RB
distinct/JJ
protein/NN
complexes/NNS
,/,
TOR/NN
complex1/NN
(/(
TORC1/NN
)/)
and/CC
TOR/NN
complex/NN
2/CD
(/(
TORC2/NN
)/)
(/(
Loewith/JJ
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Especially/RB
,/,
rapamycinsensitive/JJ
TORC1/NN
pathway/NN
plays/VBZ
critical/JJ
roles/NNS
in/IN
cell/NN
growth/NN
./.
====================
TORC1/NN
affects/VBZ
ribosome/NN
biogenesis/NN
by/IN
regulating/VBG
transcription/NN
of/IN
all/DT
three/CD
kinds/NNS
of/IN
RNA/NN
polymerases/NNS
(/(
Mayer/NN
and/CC
Grummt/NN
,/,
2006/CD
)/)
./.
====================
Inactivation/NN
of/IN
TORC1/NN
results/NNS
in/IN
several/JJ
physiological/JJ
characteristics/NNS
of/IN
nutrient/JJ
starvation/NN
,/,
including/VBG
induction/NN
of/IN
autophagy/NN
(/(
Rohde/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
Recently/RB
,/,
it/PRP
has/VBZ
been/VBN
highlighted/VBN
that/DT
TOR/NN
signaling/NN
is/VBZ
deeply/RB
involved/VBN
in/IN
eukaryotic/JJ
cell/NN
aging/NN
and/CC
agingrelated/JJ
diseases/NNS
./.
====================
Inhibition/NN
of/IN
TOR/NN
signaling/NN
extends/NNS
lifespan/NN
in/IN
yeast/NN
,/,
nematode/RB
and/CC
fruitfly/RB
(/(
Jia/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Powers/NNS
et/FW
al./FW
,/,
2006/CD
;/:
Zid/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Although/IN
the/DT
knowledge/NN
about/RB
TOR/NN
pathway/NN
has/VBZ
been/VBN
greatly/RB
expanded/VBN
by/IN
intensive/JJ
research/NN
over/IN
the/DT
last/JJ
two/CD
decades/NNS
,/,
there/EX
are/VBP
still/RB
many/JJ
unknown/JJ
factors/NNS
in/IN
the/DT
upstream/JJ
and/CC
downstream/JJ
of/IN
TOR/NN
signaling/NN
pathway/NN
due/JJ
to/TO
its/PRP$
complexity/NN
and/CC
crosstalk/NN
with/IN
other/JJ
signaling/NN
pathways/NNS
./.
====================
According/VBG
to/TO
the/DT
central/JJ
dogma/NN
of/IN
molecular/JJ
biology/NN
suggested/VBD
about/IN
50/CD
years/NNS
ago/NN
(/(
Crick/NN
,/,
1958/CD
)/)
,/,
most/JJS
of/IN
the/DT
genetic/JJ
information/NN
in/IN
DNA/NN
is/VBZ
finally/RB
transferred/VBN
to/TO
proteins/NNS
./.
====================
Proteins/NNS
,/,
the/DT
final/JJ
products/NNS
in/IN
the/DT
central/JJ
dogma/NN
,/,
are/VBP
not/RB
only/RB
fundamental/JJ
components/NNS
of/IN
living/JJ
cells/NNS
but/CC
also/RB
mediators/NNS
of/IN
most/JJS
of/IN
the/DT
cellular/JJ
processes/NNS
./.
====================
Thus/RB
,/,
to/TO
broaden/JJ
our/PRP$
understanding/NN
of/IN
cellular/JJ
functions/NNS
and/CC
processes/NNS
,/,
it/PRP
is/VBZ
essential/JJ
to/TO
know/VB
the/DT
mechanisms/NNS
how/WRB
to/TO
regulate/VB
the/DT
activity/NN
or/CC
abundance/NN
of/IN
each/DT
protein/NN
./.
====================
On/IN
these/DT
days/NNS
,/,
rapid/JJ
developing/VBG
technology/NN
in/IN
life/NN
science/NN
makes/VBZ
it/PRP
possible/JJ
to/TO
study/VB
proteins/NNS
at/IN
a/DT
largescale/JJ
or/CC
proteomic/JJ
level/NN
./.
====================
Proteomics/NNS
has/VBZ
become/VBN
well/RB
established/VBN
as/IN
a/DT
term/NN
for/IN
studying/VBG
proteins/NNS
at/IN
a/DT
large/JJ
scale/JJ
./.
====================
Therefore/RB
,/,
proteomic/JJ
research/NN
might/MD
be/VB
very/RB
helpful/JJ
in/IN
understanding/VBG
the/DT
precise/JJ
cellular/JJ
functions/NNS
and/CC
processes/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
to/TO
gain/VB
a/DT
novel/JJ
insight/NN
into/IN
TOR/NN
signaling/NN
pathway/NN
in/IN
Saccharomyces/NN
cerevisiae/NN
,/,
we/PRP
sought/VBD
to/TO
analyze/VB
proteomic/JJ
expression/NN
changes/NNS
in/IN
yeast/NN
cells/NNS
treated/VBN
with/IN
or/CC
without/IN
rapamycin/NN
./.
====================
To/TO
determine/VB
proteomic/JJ
expression/NN
changes/NNS
in/IN
yeast/NN
,/,
we/PRP
took/VBD
advantage/NN
of/IN
a/DT
collection/NN
of/IN
4159/CD
green/VBN
fluorescent/JJ
protein/NN
(/(
GFP/NN
)/)
tagged/VBD
yeast/NN
strains/NNS
(/(
Huh/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Previously/RB
,/,
several/JJ
researches/NNS
have/VBP
used/VBN
the/DT
yeast/NN
GFPtagged/JJ
collection/NN
for/IN
rapid/JJ
and/CC
precise/JJ
highthroughput/JJ
measurement/NN
of/IN
protein/NN
abundances/VBZ
which/WDT
could/MD
be/VB
represented/VBN
by/IN
GFP/NN
intensities/VBZ
tagged/VBN
on/IN
each/DT
protein/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Newman/JJ
et/FW
al./FW
,/,
2006/CD
;/:
Song/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
From/IN
our/PRP$
proteomic/JJ
analysis/NN
,/,
we/PRP
show/VBP
that/IN
83/CD
proteins/NNS
are/VBP
decreased/VBN
whereas/IN
32/CD
proteins/NNS
are/VBP
increased/VBN
by/IN
rapamycin/NN
treatment/NN
./.
====================
We/PRP
suggest/VBP
that/IN
these/DT
115/CD
proteins/NNS
may/MD
be/VB
directly/RB
or/CC
indirectly/RB
involved/VBN
in/IN
TOR/NN
signaling/NN
and/CC
can/MD
serve/VB
as/IN
candidates/NNS
for/IN
further/JJ
investigation/NN
of/IN
the/DT
effectors/NNS
of/IN
TOR/NN
pathway/NN
./.
====================
Further/RB
study/NN
with/IN
these/DT
candidates/NNS
may/MD
reveal/VB
important/JJ
insights/NNS
into/IN
TOR/NN
signaling/NN
pathway/NN
./.
====================
4159/CD
GFP-tagged/JJ
yeast/NN
strains/NNS
expressing/VBG
GFP/NN
fusion/NN
proteins/NNS
(/(
Huh/NNP
et/FW
al./FW
,/,
2003/CD
)/)
were/VBD
used/VBN
to/TO
monitor/VB
changes/NNS
in/IN
protein/NN
levels/NNS
./.
====================
A/DT
synthetic/JJ
complete/JJ
medium/NN
(/(
SC/NN
;/:
0.67/CD
%/NN
yeast/NN
nitrogen/NN
base/NN
without/IN
amino/NN
acids/NNS
,/,
2/CD
%/NN
glucose/NN
)/)
were/VBD
prepared/VBN
as/IN
previously/RB
described/VBN
(/(
Sherman/NNP
,/,
2002/CD
)/)
./.
====================
Cells/NNS
were/VBD
grown/VBN
to/TO
the/DT
midlog/NN
phase/NN
in/IN
SC/NN
medium/NN
at/IN
30oC/NN
./.
====================
Rapamycin/NN
(/(
Tecoland/NN
)/)
was/VBD
dissolved/VBN
in/IN
DMSO/NN
and/CC
used/VBN
at/IN
200/CD
ng/ml/NN
concentration/NN
./.
====================
GFP-tagged/JJ
yeast/NN
strains/NNS
were/VBD
grown/VBN
to/TO
the/DT
midlog/NN
phase/NN
in/IN
96/CD
deep-well/NN
plates/VBZ
(/(
Bioneer/NNP
)/)
./.
====================
The/DT
optical/JJ
density/NN
(/(
OD/NN
)/)
and/CC
fluorescence/NN
intensity/NN
of/IN
the/DT
cells/NNS
were/VBD
measured/VBN
in/IN
clear-bottom/JJ
,/,
96-well/JJ
plates/VBZ
(/(
Greiner/NN
Bio/NNP
One/CD
)/)
with/IN
a/DT
multilabel/JJ
microplate/NN
reader/NN
(/(
EnVision/NN
;/:
PerkinElmer/NN
)/)
./.
====================
The/DT
OD/NN
was/VBD
measured/VBN
using/VBG
a/DT
595nm/JJ
filter/NN
./.
====================
Fluorescence/NN
intensity/NN
was/VBD
measured/VBN
using/VBG
an/DT
excitation/NN
filter/NN
of/IN
488/CD
nm/NN
and/CC
an/DT
emission/NN
filter/NN
of/IN
535/CD
nm/NN
./.
====================
To/TO
eliminate/VB
cellular/JJ
autofluorescence/NN
,/,
we/PRP
set/VBP
running/VBG
median/JJ
through/IN
OD/NN
with/IN
3/CD
parameters/NNS
(/(
window/NN
size/NN
:/:
0.01/CD
OD/NN
;/:
slide/JJ
size/NN
:/:
0.002/CD
OD/NN
;/:
count/VBP
threshold/JJ
:/:
50/CD
)/)
./.
====================
A/DT
relative/JJ
abundance/NN
of/IN
each/DT
protein/NN
was/VBD
calculated/VBN
as/IN
:/:
Relative/JJ
abundance/NN
of/IN
protein/NN
=/JJ
fluorescence/NN
of/IN
proteinOD/NN
-/:
running/VBG
medianODwhere/VBP
fluorescence/NN
of/IN
proteinOD/NN
is/VBZ
a/DT
GFP/NN
intensity/NN
of/IN
each/DT
strain/NN
showing/VBG
a/DT
certain/JJ
OD/NN
and/CC
running/JJ
medianOD/NN
is/VBZ
an/DT
average/JJ
GFP/NN
intensity/NN
of/IN
all/DT
strains/NNS
showing/VBG
the/DT
corresponding/JJ
OD/NN
./.
====================
To/TO
exclude/VB
an/DT
experimental/JJ
variation/NN
causing/VBG
plate/VBP
tendency/NN
,/,
standard/RB
deviations/NNS
of/IN
nontagged/JJ
cells/NNS
and/CC
44/CD
plates/VBZ
containing/VBG
4159/CD
GFPtagged/JJ
cells/NNS
between/IN
GFP/NN
intensity/NN
measurements/NNS
at/IN
0/CD
,/,
1/CD
and/CC
2/CD
hr/NN
were/VBD
calculated/VBN
,/,
and/CC
14/CD
plates/VBZ
showing/VBG
higher/JJR
standard/RB
deviations/NNS
than/IN
those/DT
of/IN
half/JJ
of/IN
nontagged/JJ
cells/NNS
were/VBD
excluded/VBN
for/IN
further/JJ
analysis/NN
./.
====================
Among/IN
the/DT
remaining/VBG
proteins/NNS
,/,
we/PRP
selected/VBD
115/CD
proteins/NNS
showing/VBG
higher/JJR
relative/JJ
abundance/NN
values/NNS
than/IN
1.65×/CD
(/(
standard/JJ
deviations/NNS
of/IN
nontagged/JJ
cells/NNS
)/)
./.
====================
Physiological/JJ
functions/NNS
of/IN
a/DT
protein/NN
can/MD
be/VB
regulated/VBN
at/IN
the/DT
level/NN
of/IN
abundance/NN
./.
====================
Protein/NN
abundance/NN
changes/NNS
result/NN
from/IN
a/DT
number/NN
of/IN
regulatory/JJ
mechanisms/NNS
ranging/VBG
from/IN
transcription/NN
to/TO
posttranslational/JJ
modification/NN
./.
====================
Thus/RB
,/,
change/NN
in/IN
protein/NN
abundance/NN
can/MD
suggest/VB
a/DT
possibility/NN
of/IN
alteration/NN
in/IN
physiological/JJ
roles/NNS
of/IN
the/DT
protein/NN
./.
====================
As/IN
a/DT
key/JJ
regulatory/JJ
signaling/NN
pathway/NN
of/IN
eukaryotic/JJ
cell/NN
growth/NN
(/(
Wullschleger/NN
et/FW
al./FW
,/,
2006/CD
)/)
,/,
TOR/NN
pathway/NN
may/MD
be/VB
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
protein/NN
abundances/VBZ
./.
====================
Based/VBN
on/IN
this/DT
consideration/NN
,/,
we/PRP
hypothesized/VBD
that/IN
protein/NN
abundance/NN
changes/NNS
induced/VBN
by/IN
rapamycin/NN
,/,
a/DT
specific/JJ
inhibitor/NN
of/IN
TORC1/NN
,/,
might/MD
indicate/VBP
involvement/NN
of/IN
the/DT
protein/NN
in/IN
TOR/NN
pathway/NN
./.
====================
To/TO
test/VB
this/DT
hypothesis/NN
,/,
we/PRP
carried/VBD
out/RP
a/DT
quantitative/JJ
proteomic/JJ
analysis/NN
with/IN
or/CC
without/IN
rapamycin/NN
treatment/NN
./.
====================
For/IN
a/DT
quantification/NN
of/IN
the/DT
yeast/NN
proteome/JJ
,/,
we/PRP
took/VBD
advantage/NN
of/IN
a/DT
collection/NN
of/IN
4159/CD
GFPtagged/JJ
yeast/NN
strains/NNS
(/(
Huh/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Recently/RB
,/,
several/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
the/DT
yeast/NN
GFPtagged/JJ
collection/NN
can/MD
be/VB
used/VBN
for/IN
profiling/VBG
proteome/JJ
expression/NN
by/IN
measuring/VBG
the/DT
fluorescence/NN
intensity/NN
of/IN
each/DT
GFPtagged/JJ
strain/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Newman/JJ
et/FW
al./FW
,/,
2006/CD
;/:
Song/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
To/TO
perform/VB
a/DT
proteomic/JJ
quantification/NN
of/IN
the/DT
fluorescence/NN
intensities/NNS
of/IN
the/DT
GFPtagged/JJ
yeast/NN
collection/NN
rapidly/RB
and/CC
precisely/RB
,/,
we/PRP
used/VBD
a/DT
multilabel/JJ
microplate/NN
reader/NN
that/DT
could/MD
simultaneously/RB
analyze/VB
the/DT
intensities/NNS
of/IN
96/CD
GFPtagged/JJ
yeast/NN
cells/NNS
./.
====================
The/DT
validity/NN
of/IN
GFPintensity/NN
data/NNS
from/IN
a/DT
multilabel/JJ
microplate/NN
reader/NN
was/VBD
confirmed/VBN
in/IN
our/PRP$
previous/JJ
study/NN
(/(
Song/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
We/PRP
measured/VBD
the/DT
fluorescence/NN
of/IN
4159/CD
GFPtagged/JJ
yeast/NN
strains/NNS
grown/VBN
to/TO
the/DT
mid/JJ
logphase/NN
with/IN
or/CC
without/IN
treatment/NN
of/IN
200/CD
ng/ml/NN
rapamycin/NN
for/IN
1/CD
hr/NN
./.
====================
During/IN
the/DT
data/NNS
processing/NN
,/,
we/PRP
found/VBD
that/IN
about/RB
40/CD
%/NN
of/IN
raw/JJ
data/NNS
were/VBD
not/RB
appropriate/JJ
for/IN
further/JJ
analysis/NN
and/CC
decided/VBD
to/TO
exclude/VB
these/DT
data/NNS
./.
====================
The/DT
remaining/VBG
2422/CD
GFP/NN
intensity/NN
changes/NNS
under/IN
rapamycin/NN
treatment/NN
were/VBD
further/RBR
analyzed/VBD
./.
====================
Consequently/RB
,/,
we/PRP
found/VBD
that/IN
83/CD
proteins/NNS
were/VBD
significantly/RB
decreased/VBD
by/IN
rapamycin/NN
treatment/NN
whereas/IN
32/CD
proteins/NNS
were/VBD
increased/VBN
under/IN
the/DT
same/JJ
condition/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
These/DT
115/CD
proteins/NNS
that/WDT
underwent/JJ
significant/JJ
protein/NN
abundance/NN
changes/NNS
under/IN
rapamycin/NN
treatment/NN
are/VBP
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
In/IN
the/DT
previous/JJ
study/NN
,/,
DNA/NN
microarray/NN
was/VBD
used/VBN
to/TO
examine/VB
the/DT
genome-wide/NN
transcription/NN
alteration/NN
under/IN
rapamycin/NN
treatment/NN
(/(
Hardwick/JJ
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
Since/IN
a/DT
change/NN
in/IN
protein/NN
level/NN
usually/RB
originates/VBZ
from/IN
an/DT
alteration/NN
in/IN
the/DT
gene/NN
expression/NN
,/,
we/PRP
tried/VBD
to/TO
compare/VB
the/DT
protein/NN
abundance/NN
changes/NNS
with/IN
the/DT
mRNA/NN
level/NN
changes/NNS
under/IN
rapamycin/NN
treatment/NN
./.
====================
Among/IN
the/DT
115/CD
proteins/NNS
that/WDT
showed/VBD
significant/JJ
protein/NN
abundance/NN
changes/NNS
,/,
37/CD
proteins/NNS
also/RB
showed/VBD
≥2-fold/JJ
changes/NNS
in/IN
the/DT
mRNA/NN
level/NN
under/IN
rapamycin/NN
treatment/NN
./.
====================
We/PRP
investigated/VBD
the/DT
correlation/NN
between/IN
the/DT
mRNA/NN
and/CC
protein/NN
level/NN
changes/NNS
for/IN
these/DT
37/CD
proteins/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
Pearson/NN
correlation/NN
analysis/NN
of/IN
37/CD
proteins/NNS
showed/VBD
a/DT
positive/JJ
correlation/NN
between/IN
the/DT
mRNA/NN
and/CC
protein/NN
expression/NN
except/IN
for/IN
3/CD
proteins/NNS
,/,
Rck2/NN
,/,
Eno1/NN
and/CC
Mak10/NN
./.
====================
These/DT
3/CD
proteins/NNS
showed/VBD
a/DT
negative/JJ
correlation/NN
,/,
and/CC
exhibited/VBD
an/DT
increase/NN
in/IN
protein/NN
abundance/NN
while/IN
their/PRP$
mRNA/NN
levels/NNS
were/VBD
decreased/VBN
under/IN
rapamycin/NN
treatment/NN
./.
====================
The/DT
37/CD
proteins/NNS
showing/VBG
significant/JJ
changes/NNS
in/IN
the/DT
protein/NN
and/CC
mRNA/NN
level/NN
under/IN
rapamycin/NN
treatment/NN
were/VBD
classified/VBN
into/IN
the/DT
Gene/NN
Ontology/NN
(/(
GO/NN
)/)
categories/NNS
(/(
Ashburner/NN
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
As/IN
shown/VBN
in/IN
Table/JJ
2/CD
,/,
the/DT
37/CD
proteins/NNS
were/VBD
enriched/VBN
especially/RB
in/IN
the/DT
GO/NN
categories/NNS
related/JJ
with/IN
protein/NN
synthesis/NN
./.
====================
This/DT
enrichment/JJ
resulted/VBD
from/IN
inclusion/NN
of/IN
16/CD
ribosomal/JJ
proteins/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
TOR/NN
signaling/NN
pathway/NN
controls/VBZ
translation/NN
initiation/NN
by/IN
regulating/VBG
eIF2α/JJ
(/(
Cherkasova/NNP
and/CC
Hinne/JJ
busch/DT
,/,
2003/CD
)/)
and/CC
also/RB
plays/VBZ
critical/JJ
roles/NNS
in/IN
expression/NN
of/IN
ribosomal/JJ
protein/NN
genes/NNS
(/(
Powers/NNS
and/CC
Walter/NN
,/,
1999/CD
)/)
./.
====================
Therefore/RB
,/,
the/DT
enrichment/JJ
in/IN
the/DT
GO/NN
categories/NNS
related/JJ
with/IN
protein/NN
synthesis/NN
is/VBZ
consistent/JJ
with/IN
the/DT
previous/JJ
reports/NNS
./.
====================
Notably/RB
,/,
rapamycin/NN
treatment/NN
inhibited/VBD
guanosine5/NN
'/``
triphosphate/NN
(/(
GTP/NN
)/)
biosynthetic/JJ
process/NN
by/IN
decreasing/VBG
the/DT
protein/NN
and/CC
mRNA/NN
level/NN
of/IN
Imd2/NN
and/CC
Imd3/NN
./.
====================
Imd2/NN
and/CC
Imd3/NN
are/VBP
important/JJ
enzymes/NNS
for/IN
de/FW
novo/FW
GTP/NN
synthesis/NN
whose/WP$
abundance/NN
and/CC
activity/NN
are/VBP
correlated/VBN
with/IN
cellular/JJ
growth/NN
rate/NN
(/(
Jackson/NN
et/FW
al./FW
,/,
1975/CD
)/)
./.
====================
It/PRP
is/VBZ
likely/JJ
that/IN
repression/NN
of/IN
de/FW
novo/FW
GTP/NN
synthesis/NN
caused/VBD
by/IN
decrease/NN
of/IN
Imd2/NN
and/CC
Imd3/NN
under/IN
rapamycin/NN
treatment/NN
may/MD
consequently/RB
contribute/VBP
to/TO
inhibition/NN
of/IN
cell/NN
growth/NN
./.
====================
This/DT
is/VBZ
consistent/JJ
with/IN
the/DT
critical/JJ
roles/NNS
of/IN
TOR/NN
pathway/NN
in/IN
eukaryotic/JJ
cell/NN
growth/NN
regulation/NN
./.
====================
A/DT
number/NN
of/IN
regulatory/JJ
mechanisms/NNS
are/VBP
involved/VBN
in/IN
production/NN
of/IN
a/DT
protein/NN
./.
====================
The/DT
expression/NN
level/NN
of/IN
mRNA/NN
is/VBZ
an/DT
important/JJ
clue/NN
to/TO
understand/VB
cellular/JJ
processes/NNS
and/CC
functions/NNS
./.
====================
However/RB
,/,
because/IN
of/IN
posttranscriptional/JJ
mechanisms/NNS
controlling/VBG
the/DT
translation/NN
rate/NN
(/(
McCarthy/NNP
,/,
1998/CD
)/)
and/CC
differential/JJ
half-lives/NNS
of/IN
mRNAs/NNS
(/(
Varshavsky/NNP
,/,
1996/CD
)/)
,/,
mRNA/NN
level/NN
alone/RB
does/VBZ
not/RB
reflect/VB
biological/JJ
events/NNS
precisely/RB
./.
====================
Therefore/RB
,/,
a/DT
quantitative/JJ
proteomic/JJ
analysis/NN
profiling/VBG
the/DT
whole/JJ
protein/NN
expressions/NNS
is/VBZ
very/RB
useful/JJ
for/IN
determination/NN
of/IN
cellular/JJ
processes/NNS
and/CC
functions/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
systematically/RB
analyzed/VBD
protein/NN
abundance/NN
changes/NNS
using/VBG
the/DT
yeast/NN
GFPtagged/JJ
collection/NN
under/IN
inhibition/NN
of/IN
TOR/NN
signaling/NN
by/IN
rapamycin/NN
treatment/NN
and/CC
showed/VBD
that/IN
the/DT
proteins/NNS
engaged/VBN
in/IN
protein/NN
synthesis/NN
are/VBP
the/DT
major/JJ
regulatory/JJ
targets/NNS
of/IN
TOR/NN
pathway/NN
./.
====================
Especially/RB
,/,
16/CD
ribosomal/JJ
proteins/NNS
are/VBP
included/VBN
in/IN
the/DT
target/NN
list/NN
./.
====================
This/DT
result/NN
is/VBZ
consistent/JJ
with/IN
the/DT
previous/JJ
reports/NNS
./.
====================
However/RB
,/,
although/IN
16/CD
ribosomal/JJ
proteins/NNS
showed/VBD
an/DT
abrupt/RB
decrease/NN
in/IN
protein/NN
abundance/NN
by/IN
rapamycin/NN
treatment/NN
,/,
some/DT
other/JJ
ribosomal/JJ
proteins/NNS
with/IN
long/JJ
protein/NN
half-lives/VBZ
,/,
such/JJ
as/IN
Rpl43a/NN
and/CC
Rps19a/NN
(/(
Belle/NNP
et/FW
al./FW
,/,
2006/CD
)/)
,/,
did/VBD
not/RB
show/VB
any/DT
alteration/NN
in/IN
protein/NN
level/NN
under/IN
rapamycin/NN
treatment/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
It/PRP
is/VBZ
intriguing/JJ
that/DT
abundance/VBP
of/IN
some/DT
ribosomal/JJ
proteins/NNS
is/VBZ
immediately/RB
influenced/VBN
by/IN
TOR/NN
inhibition/NN
while/IN
that/DT
of/IN
other/JJ
ribosomal/JJ
proteins/NNS
does/VBZ
not/RB
have/VB
any/DT
relationship/NN
with/IN
TOR/NN
pathway/NN
./.
====================
Further/RB
studies/NNS
on/IN
this/DT
difference/NN
among/IN
ribosomal/JJ
proteins/NNS
will/MD
be/VB
helpful/JJ
in/IN
elucidating/VBG
the/DT
regulatory/JJ
mechanism/NN
of/IN
TOR/NN
signaling/NN
pathway/NN
involved/VBN
in/IN
translational/JJ
control/NN
./.
====================
It/PRP
is/VBZ
worthy/NN
to/TO
note/VB
that/IN
abundance/VBP
of/IN
Imd2/NN
and/CC
Imd3/NN
,/,
the/DT
enzymes/NNS
for/IN
de/FW
novo/FW
GTP/NN
synthesis/NN
,/,
is/VBZ
decreased/VBN
under/IN
inhibition/NN
of/IN
TORC1/NN
./.
====================
GTP/NN
is/VBZ
essential/JJ
to/TO
signal/VB
transduction/NN
and/CC
is/VBZ
converted/VBN
to/TO
GDP/NN
through/IN
the/DT
action/NN
of/IN
GTPases/NN
./.
====================
Recently/RB
,/,
it/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
yeast/NN
Rag/JJ
GTPases/NNS
,/,
Gtr1/NNP
and/CC
Gtr2/NN
,/,
act/VBP
as/IN
upstream/RB
regulators/NNS
of/IN
TORC1/NN
and/CC
play/VBP
critical/JJ
roles/NNS
in/IN
coupling/VBG
amino/NN
acid/NN
signal/NN
to/TO
TORC1/NN
(/(
Binda/NN
et/FW
al./FW
,/,
2009/CD
;/:
Kim/NN
et/FW
al./FW
,/,
2008/CD
;/:
Sancak/NN
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
The/DT
fact/NN
that/IN
TORC1/NN
is/VBZ
involved/VBN
in/IN
GTP/NN
biosynthesis/NN
by/IN
regulating/VBG
the/DT
protein/NN
level/NN
of/IN
Imd2/NN
and/CC
Imd3/NN
suggests/VBZ
that/IN
TOR/NN
pathway/NN
may/MD
affect/VB
the/DT
activity/NN
of/IN
several/JJ
GTPbinding/JJ
proteins/NNS
including/VBG
Gtr1/NN
and/CC
Gtr2/NN
./.
====================
It/PRP
will/MD
be/VB
interesting/JJ
to/TO
investigate/VB
if/IN
TOR/NN
pathway/NN
is/VBZ
really/RB
involved/VBN
in/IN
regulation/NN
of/IN
the/DT
activity/NN
of/IN
GTPbinding/JJ
proteins/NNS
./.
====================
Previously/RB
,/,
genomewide/NN
functional/JJ
profiling/VBG
using/VBG
the/DT
yeast/NN
deletion/NN
library/NN
has/VBZ
identified/VBN
396/CD
mutant/JJ
strains/NNS
showing/VBG
altered/JJ
sensitivity/NN
to/TO
rapamycin/NN
(/(
Xie/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
We/PRP
compared/VBD
this/DT
functional/JJ
genomic/JJ
result/NN
with/IN
our/PRP$
proteomic/JJ
result/NN
./.
====================
Among/IN
the/DT
37/CD
genes/NNS
that/WDT
show/VBP
significant/JJ
changes/NNS
in/IN
the/DT
mRNA/NN
and/CC
protein/NN
level/NN
under/IN
rapamycin/NN
treatment/NN
,/,
only/RB
two/CD
genes/NNS
,/,
PBI2/NN
and/CC
MAK10/NN
,/,
show/VBP
alteration/NN
in/IN
rapamycin/NN
sensitivity/NN
upon/IN
deletion/NN
./.
====================
This/DT
inconsistency/NN
between/IN
the/DT
genomic/JJ
and/CC
proteomic/JJ
responses/NNS
to/TO
rapamycin/NN
is/VBZ
presumed/VBN
to/TO
be/VB
due/JJ
to/TO
differences/NNS
in/IN
the/DT
experimental/JJ
approaches/NNS
for/IN
monitoring/VBG
rapamycin/NN
effects/NNS
,/,
and/CC
is/VBZ
also/RB
indicative/JJ
of/IN
a/DT
possibility/NN
that/IN
TOR/NN
signaling/NN
pathway/NN
influences/VBZ
cell/NN
physiology/NN
at/IN
numerous/JJ
levels/NNS
from/IN
genes/NNS
to/TO
proteins/NNS
./.
====================
Thus/RB
,/,
understanding/VBG
the/DT
difference/NN
between/IN
the/DT
genomic/JJ
and/CC
proteomic/JJ
responses/NNS
to/TO
rapamycin/NN
will/MD
give/VB
further/JJ
insights/NNS
into/IN
the/DT
regulatory/JJ
mechanisms/NNS
of/IN
TOR/NN
signaling/NN
pathway/NN
./.
====================
